<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-0015</journal-id>
<journal-title><![CDATA[Medicina Legal de Costa Rica]]></journal-title>
<abbrev-journal-title><![CDATA[Med. leg. Costa Rica]]></abbrev-journal-title>
<issn>1409-0015</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Medicina Forense]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-00152018000100044</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Generalidades de cáncer de mama para médico general]]></article-title>
<article-title xml:lang="en"><![CDATA[Breast cancer overview for general practitioner]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Madrigal Ureña]]></surname>
<given-names><![CDATA[Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mora Rosenkranz]]></surname>
<given-names><![CDATA[Brian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<volume>35</volume>
<numero>1</numero>
<fpage>44</fpage>
<lpage>51</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-00152018000100044&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-00152018000100044&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-00152018000100044&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer de mama, es el más frecuente en mujeres; mortal si no es diagnosticado a tiempo que varía de su estadio, su histología y biología molecular. Es bien conocido, que la exposición estrogénica, es un factor de riesgo para el desarrollo de cáncer de mama, junto los antecedentes heredo familiares de primer y segundo grado y genética. El tamizaje en mujeres asintomáticas ha evidenciado que disminuye la mortalidad por el diagnóstico temprano y su diagnóstico de confirmación es la histología por biopsias con aguja gruesa. El tratamiento va depender del estadio, metástasis nodal o extranodal y la inmunohistoquímica y la disminución de la mortalidad se ha logrado con el diagnóstico oportuno y el tratamiento con cirugía y terapia antihormonal.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Breast cancer is the most frequent cancer in women; is highly mortal if not diagnosed on time depending on stage, histology and molecular biology. It is well known, that estrogenic exposure is a risk factor for developing breast cancer, together with family history in first or second negree and genetics. Screening asymptomatic women has shown to decrease mortality rates and the confirmation diagnostic is done with thick needle biopsy. The treatment depends on the stage, nodal or extranodal metastasis and immunohistochemistry and reduction of mortality rate has been accomplished with timely diagnosis and the treatment with surgery and antihormonal therapy.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de mama]]></kwd>
<kwd lng="es"><![CDATA[terapia antihormonal]]></kwd>
<kwd lng="es"><![CDATA[biología molecular]]></kwd>
<kwd lng="es"><![CDATA[biomarcadores]]></kwd>
<kwd lng="en"><![CDATA[Breast cancer]]></kwd>
<kwd lng="en"><![CDATA[antihormonal therapy]]></kwd>
<kwd lng="en"><![CDATA[molecular biology and biomarkers]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<source><![CDATA[Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. PDQ Cancer Genetics Editorial Board. PDQ Cancer Information Summaries (Internet)]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Bethesda (MD) ]]></publisher-loc>
<publisher-name><![CDATA[National Cancer Institute (US)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[Anti-estrogen therapy increases plasticity and cancer stemness of prolactin-induced ER&#940;+ mammary carcinomas. Cancer Res]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<source><![CDATA[Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol]]></source>
<year>2001</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<source><![CDATA[Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. J Natl Cancer Inst]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<source><![CDATA[STAT3 as a promising chemoresistance biomarker associated with the CD44 BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<source><![CDATA[Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas Simpson PT. J Pathol]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<source><![CDATA[Breast cancer treatment - An overview from the US National Cancer Institute (NCI) - Health Professional version. Peer-reviewed, evidence-based summaries fromthe NCI's Physician Data Query (PDQ) database]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Women's Health Initiative]]></article-title>
<source><![CDATA[Semin Reprod Med]]></source>
<year>2014</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>417-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>112816-24</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<source><![CDATA[Epstein Barr virus and invasive mammary carcinomas: EBNA, EBERs and molecular profile in a population of West Algeria. Ann Biol Clin]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients]]></article-title>
<source><![CDATA[World J Surg Oncol]]></source>
<year>2018</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2017</year>
<volume>8</volume>
<numero>62</numero>
<issue>62</issue>
<page-range>105775-89</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer]]></article-title>
<source><![CDATA[Asian Pac J Cancer Prev]]></source>
<year>2017</year>
<volume>18</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2673-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<source><![CDATA[IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer Oncogene]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Breast cancer classification: linking molecular mechanisms to disease prognosis]]></article-title>
<source><![CDATA[Brief Bioinform]]></source>
<year>2015</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>461-74</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Molecular classification of breast cancer]]></article-title>
<source><![CDATA[Virchows Arch]]></source>
<year>2014</year>
<volume>465</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lakhani]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Ellis]]></surname>
<given-names><![CDATA[IO]]></given-names>
</name>
<name>
<surname><![CDATA[Schnitt]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[van de Vijver]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[World Health Organization classification of tumours of the breast]]></source>
<year>2012</year>
<publisher-name><![CDATA[IARC, Lyon]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Refinement of breast cancer classification by molecular characterization of histological special types]]></article-title>
<source><![CDATA[J Pathol]]></source>
<year></year>
<volume>216</volume>
<page-range>141-50</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sentinel node biopsy for breast cancer: past, present, and future]]></article-title>
<source><![CDATA[Breast Cancer]]></source>
<year>2015</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>212-20</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>378</volume>
<numero>9804</numero>
<issue>9804</issue>
<page-range>1707-16</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
